GTS5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 315: | Line 315: | ||
|Eric McGinnis | |Eric McGinnis | ||
| | | | ||
|Named based on GTS5 book (page created 7/12/24). Also, content in online WHO MALE5, FEMA5, BRST5, DIG5 | |Named based on GTS5 book (page created 7/12/24). Also, content in online WHO MALE5, FEMA5, BRST5, DIG5. | ||
|- | |- | ||
|[[GTS5:Hereditary_gastric_and_breast_cancer_syndrome_(CDH1,_CTNNA1)|Hereditary gastric and breast cancer syndrome (CDH1, CTNNA1)]] | |[[GTS5:Hereditary_gastric_and_breast_cancer_syndrome_(CDH1,_CTNNA1)|Hereditary gastric and breast cancer syndrome (CDH1, CTNNA1)]] | ||
| Line 337: | Line 337: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book GTS-Specific Template (11-7-24) added 12/29/24. No other books have content. | ||
|- | |- | ||
|[[GTS5:Naevoid_basal_cell_carcinoma_syndrome_-_Gorlin_syndrome_(PTCH1,_SUFU,_GPR161)|Naevoid basal cell carcinoma syndrome - Gorlin syndrome (PTCH1, SUFU, GPR161)]] | |[[GTS5:Naevoid_basal_cell_carcinoma_syndrome_-_Gorlin_syndrome_(PTCH1,_SUFU,_GPR161)|Naevoid basal cell carcinoma syndrome - Gorlin syndrome (PTCH1, SUFU, GPR161)]] | ||
| Line 348: | Line 348: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book (page created 7/12/24). Also, content in online WHO CNS5, SKIN5, PEDS5, HAN5. | ||
|- | |- | ||
|[[GTS5:SMO-related_Curry-Jones_syndrome_(SMO)|SMO-related Curry-Jones syndrome (SMO)]] | |[[GTS5:SMO-related_Curry-Jones_syndrome_(SMO)|SMO-related Curry-Jones syndrome (SMO)]] | ||
| Line 359: | Line 359: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book GTS-Specific Template (11-7-24) added 12/29/24. No other books have content. | ||
|- | |- | ||
|[[GTS5:ELP1-related_medulloblastoma_predisposition_syndrome(ELP1)|ELP1-related medulloblastoma predisposition syndrome(ELP1)]] | |[[GTS5:ELP1-related_medulloblastoma_predisposition_syndrome(ELP1)|ELP1-related medulloblastoma predisposition syndrome(ELP1)]] | ||
| Line 370: | Line 370: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book (page created 7/12/24). Also, content in online WHO CNS5. | ||
|- | |- | ||
|[[GTS5:Osteochondromatosis_(EXT1,_EXT2)|Osteochondromatosis (EXT1, EXT2)]] | |[[GTS5:Osteochondromatosis_(EXT1,_EXT2)|Osteochondromatosis (EXT1, EXT2)]] | ||
| Line 381: | Line 381: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book GTS-Specific Template (11-7-24) added 12/29/24. No other books have content. | ||
|- | |- | ||
!'''Disease''' | !'''Disease''' | ||
| Line 403: | Line 403: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book (page created 7/12/24). Also, content in online WHO SKIN5, HAN5. | ||
|- | |- | ||
|[[GTS5:Tuberous_sclerosis_(TSC1,_TSC1)|Tuberous sclerosis (TSC1, TSC1)]] | |[[GTS5:Tuberous_sclerosis_(TSC1,_TSC1)|Tuberous sclerosis (TSC1, TSC1)]] | ||
| Line 414: | Line 414: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book Template added 7/15/24. Also, content in online WHO MALE5, CNS5, PEDS5, HAN5. | ||
|- | |- | ||
|[[GTS5:PTEN_hamartoma_tumour_syndrome_(PTEN)|PTEN hamartoma tumour syndrome (PTEN)]] | |[[GTS5:PTEN_hamartoma_tumour_syndrome_(PTEN)|PTEN hamartoma tumour syndrome (PTEN)]] | ||
| Line 425: | Line 425: | ||
|Eric McGinnis | |Eric McGinnis | ||
| | | | ||
|Named based on GTS5 book Template added 7/15/24. Also, content | |Named based on GTS5 book Template added 7/15/24. Also, content in online WHO HAN5, CNS5, FEMA5, BRST5. | ||
|- | |- | ||
|[[GTS5:Activated_Phosphatidylinositol-3-OH_kinase_δ_Syndrome_-_APDS_(PIK3CD)|Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)]] | |[[GTS5:Activated_Phosphatidylinositol-3-OH_kinase_δ_Syndrome_-_APDS_(PIK3CD)|Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)]] | ||
| Line 436: | Line 436: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book GTS-Specific Template (11-7-24) added 12/29/24. No other books have content. | ||
|- | |- | ||
|[[GTS5:Multiple_endocrine_neoplasia_type_5,_MAX_related_tumours_(MAX)|Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]] | |[[GTS5:Multiple_endocrine_neoplasia_type_5,_MAX_related_tumours_(MAX)|Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]] | ||
| Line 447: | Line 447: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book Template added 7/15/24. Also, content in online WHO ENDO5. | ||
|- | |- | ||
|[[GTS5:MAFA-related_familial_insulinomatosis_(MAFA)|MAFA-related familial insulinomatosis (MAFA)]] | |[[GTS5:MAFA-related_familial_insulinomatosis_(MAFA)|MAFA-related familial insulinomatosis (MAFA)]] | ||
| Line 458: | Line 458: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book Template added 7/15/24. Also, content in online WHO ENDO5. | ||
|- | |- | ||
|[[GTS5:Birt-Hogg-Dube_syndrome_(FLCN)|Birt-Hogg-Dube syndrome (FLCN)]] | |[[GTS5:Birt-Hogg-Dube_syndrome_(FLCN)|Birt-Hogg-Dube syndrome (FLCN)]] | ||
| Line 469: | Line 469: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book Template added 7/15/24. Also, content in online WHO MALE5. | ||
|- | |- | ||
|[[GTS5:Familial_chordoma_(TBXT)|Familial chordoma (TBXT)]] | |[[GTS5:Familial_chordoma_(TBXT)|Familial chordoma (TBXT)]] | ||
| Line 480: | Line 480: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book GTS-Specific Template (11-7-24) added 12/29/24. No other books have content. | ||
|- | |- | ||
|[[GTS5:Hyperparathyroidism_jaw_tumour_syndrome_(CDC73)|Hyperparathyroidism jaw tumour syndrome (CDC73)]] | |[[GTS5:Hyperparathyroidism_jaw_tumour_syndrome_(CDC73)|Hyperparathyroidism jaw tumour syndrome (CDC73)]] | ||
| Line 491: | Line 491: | ||
| | | | ||
| | | | ||
| | |Named based on GTS5 book GTS-Specific Template (11-7-24) added 12/29/24. No other books have content. | ||
|- | |- | ||
!'''Disease''' | !'''Disease''' | ||
| Line 534: | Line 534: | ||
|Eric McGinnis | |Eric McGinnis | ||
| | | | ||
|Named based on GTS5 book ( | |Named based on GTS5 book. GTS-Specific Template (11-7-24) added 12/29/24. Had previously added an older template on 6/24/24. Also, content in online WHO EYE5, HAN5, ENDO5, MALE5, PEDS5, CNS5, FEMA5. | ||
|- | |- | ||
|[[GTS5:SDH-deficient_tumour_syndrome_-_Hereditary_phaeochromocytoma-paraganglioma_syndromes_(SDHA,_SDHB,_SDHC,_SDHD,_SDHAF2)|SDH-deficient tumour syndrome - Hereditary phaeochromocytoma-paraganglioma syndromes (SDHA, SDHB, SDHC, SDHD, SDHAF2)]] | |[[GTS5:SDH-deficient_tumour_syndrome_-_Hereditary_phaeochromocytoma-paraganglioma_syndromes_(SDHA,_SDHB,_SDHC,_SDHD,_SDHAF2)|SDH-deficient tumour syndrome - Hereditary phaeochromocytoma-paraganglioma syndromes (SDHA, SDHB, SDHC, SDHD, SDHAF2)]] | ||
| Line 545: | Line 545: | ||
|Eric McGinnis | |Eric McGinnis | ||
| | | | ||
|Named based on GTS5 book Template added 7/15/24. Also, content in online WHO ENDO5. | |Named based on GTS5 book GTS-Specific Template (11-7-24) added 12/29/24. Had previously added an old template on 7/15/24. Also, content in online WHO ENDO5. | ||
|- | |- | ||
|[[GTS5:Hereditary_leiomyomatosis_and_renal_cell_carcinoma_syndrome_(FH)|Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]] | |[[GTS5:Hereditary_leiomyomatosis_and_renal_cell_carcinoma_syndrome_(FH)|Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]] | ||